-
ARPANSA and eBay shed light on laser dangers
Australian Radiation Protection and Nuclear Safety Agency and eBay Australia have teamed up to remind businesses and consumers about the risks caused by laser pointers. -
Improving 5G research
Scientists at Swinburne University of Technology and the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) are working together to improve the experimental design of research into 5G and future high-frequency wireless technologies. -
ARPANSA rolls out audit for brain cancer treatment
ARPANSA’s Australian Clinical Dosimetry Service (ACDS) has carried out its first live stereotactic radiosurgery (SRS) audit which supports dose accuracy in radiation therapy used to treat brain cancer. -
ARPANSA launches updated website
The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) is pleased to announce the launch of their new website. -
Updated ARPANS Regulations address human and organisational factors
Addressing human and organisational factors that impact nuclear safety is among the changes to the 2018 Australian Radiation Protection and Nuclear Safety (ARPANSA) Regulations that came into effect on 10 August 2022. -
ARPANSA to discuss misinformation as part of National Science Week
Scientists from the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) will be countering misinformation about radio waves as part of National Science Week at a free event at the Science Gallery, University of Melbourne on 17 August 2022. -
Australia provides nuclear safety assistance to Ukraine
The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) and ANSTO have coordinated with the IAEA to donate radiation measurement and personal protective equipment to Ukraine. -
Take the burn out of sunscreen testing
Exposing humans to ultraviolet radiation to test sunscreen effectiveness should be phased out, according to scientists and cancer experts. -
ARPANSA updates radiation dose conversion factors
Calculating exposure from naturally occurring radioactive material (NORM) has been standardised by the Australian Radiation Protection and Nuclear Safety Agency to encourage national uniformity and ongoing alignment with international best practice. -
ARPANSA Boosts UV Protection Globally
ARPANSA has teamed up with Cancer Council Victoria and the Australian Bureau of Meteorology to create a SunSmart Global UV app. -
ARPANSA releases advisory note on public health considerations for disposal of radioactive waste
ARPANSA has released an advisory note on the public health considerations for disposal of radioactive waste. -
-
ARPANSA leads world first in film dosimetry
ARPANSA is working with the International Atomic Energy Agency (IAEA) and dosimetry auditors globally to develop a world first film dosimetry intercomparison tool. -
Recruitment underway for ARPANSA Chief Radiation Health Scientist and Head of Radiation Health Services Branch
Recruitment is currently underway for the next Chief Radiation Health Scientist and Head of Radiation Health Services Branch of ARPANSA. -
Laser focus on illegal imports
Illegal laser pointers that are being imported into the country due to incorrect product labelling is an issue being pinpointed to Australia’s Freight and Trade Alliance this month by ARPANSA scientist Dr Chris Brzozek. -
ARPANSA and RMIT to collaborate on new EME research
ARPANSA has provided funding to RMIT to investigate the impact of non-ionising radiation on cell permeability. This research is funded as the first ‘major project’ under ARPANSA’s new EME Program Research Framework. -
ARPANSA reviews risks of cosmetic procedures
ARPANSA experts have published an article in Public Health Research and Practice, a journal of the Sax Institute, that calls for more research into the use of non-ionising radiation for cosmetic purposes. -
ARPANSA farewells CEO Carl-Magnus Larsson and welcomes new CEO Gillian Hirth
The Australian Government announces the appointment of Dr Gillian Hirth as Chief Executive Officer (CEO) of ARPANSA following the retirement of current CEO, Dr Carl-Magnus Larsson.
